5 Cannabis Research Studies Worth Reading in 2026
A roundup of recent peer-reviewed cannabis studies covering terpene entourage effects, edible metabolism, minor cannabinoids, sleep, and long-term use patterns.

Cannabis science is moving faster than ever. With legalization expanding globally and research barriers falling, we are seeing more rigorous, peer-reviewed work on how cannabinoids and terpenes actually work. Here are five studies from recent years that are worth your time.
1. Terpene Entourage Effects: More Than Aromatherapy
The "entourage effect" has been a buzzword in cannabis for years, but recent research is adding substance to the claim. A 2025 study published in Cannabis and Cannabinoid Research demonstrated that specific terpene-cannabinoid combinations produced measurably different effects in mouse models compared to isolated THC.
Myrcene and linalool enhanced the sedative properties of THC, while limonene and pinene appeared to counteract some of the anxiety-producing effects. The takeaway for consumers: the terpene profile of your strain matters, not just the THC percentage.
This is exactly why we built the terpene data into our Strain Database. Understanding a strain's terpene profile gives you better information than THC alone.
2. Edible Metabolism: Why Onset Times Vary So Much
A pharmacokinetic study in the Journal of Cannabis Research tracked blood THC levels in 48 participants after consuming standardized edible doses. The results confirmed what many users already suspected: onset time varied from 20 minutes to over 3 hours across participants, even with identical doses.
The study identified liver enzyme activity (specifically CYP2C9 variants) as the strongest predictor of onset time. People with certain genetic variants metabolized edibles significantly faster. This research supports the "start low, go slow" advice and explains why your friend might feel an edible in 30 minutes while you wait two hours.
3. Minor Cannabinoids: CBG and CBC Show Promise
THC and CBD have dominated the conversation, but minor cannabinoids are getting their turn in the spotlight. A 2025 review in Frontiers in Pharmacology compiled data from 23 studies on cannabigerol (CBG) and cannabichromene (CBC).

